NeuroSense Therapeutics Ltd. - Ordinary Shares (NRSN)
NRSN moved a median of -0.68% 30 minutes after news, and -1.70% by the close. How NRSN actually reacts to news — the realized, point-in-time move the market made, measured across 260 labeled events over the last three years with zero look-ahead.
NRSN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 38% | 248 |
| 30-min | -0.68% | 44% | 260 |
| 60-min | -1.41% | 36% | 260 |
| to close | -1.70% | 33% | 258 |
| Middle 50% of NRSN reactions | -3.23% to +1.98% |
|---|---|
| Median reaction (30-min) | -0.68% |
| Measured reactions | 260 |
Half of all NeuroSense Therapeutics Ltd. - Ordinary Shares news events land between -3.23% and +1.98% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when NRSN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NRSN's baseline. Nothing else.
Recent NRSN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K NeuroSense Therapeutics For: Oct 13 | SEC filing · Form 6-K | SEC EDGAR | +9.05% | +0.58% | |
| NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones | Press release | PR Newswire | +9.05% | +0.58% | |
| Form 6-K NeuroSense Therapeutics For: Oct 02 | SEC filing · Form 6-K | SEC EDGAR | -2.46% | -0.74% | |
| NeuroSense Provides Update on Nasdaq Listing Compliance | Press release | PR Newswire | -2.46% | -0.74% | |
| NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference | Press release | PR Newswire | -0.36% | -9.73% | |
| Form 6-K NeuroSense Therapeutics For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +3.47% | -26.19% | |
| NeuroSense Provides Business Update and Progress for the First Half of 2026 | Press release | PR Newswire | +3.47% | -26.19% | |
| NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference | Press release | PR Newswire | -1.45% | -12.63% | |
| Form 6-K NeuroSense Therapeutics For: Sep 09 | SEC filing · Form 6-K | SEC EDGAR | -1.45% | -12.63% | |
| NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS | Press release | PR Newswire | -4.78% | -5.18% | |
| Form 6-K NeuroSense Therapeutics For: Aug 27 | SEC filing · Form 6-K | SEC EDGAR | -4.52% | -4.46% | |
| Form 6-K NeuroSense Therapeutics For: Aug 13 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -2.12% | |
| NeuroSense Issues CEO Letter to Shareholders | Press release | PR Newswire | -0.93% | -5.46% | |
| Form 6-K NeuroSense Therapeutics For: Aug 06 | SEC filing · Form 6-K | SEC EDGAR | -3.47% | -8.51% | |
| NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada | Press release | PR Newswire | +2.39% | -6.85% | |
| Form EFFECT NeuroSense Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | +7.63% | +18.83% | |
| Form 6-K NeuroSense Therapeutics For: Jul 31 | SEC filing · Form 6-K | SEC EDGAR | +7.63% | +18.83% | |
| Form F-3/A NeuroSense Therapeutics | SEC filing · Form F-3 | SEC EDGAR | +1.23% | -3.08% | |
| Form 6-K NeuroSense Therapeutics For: Jul 22 | SEC filing · Form 6-K | SEC EDGAR | +1.13% | -4.45% | |
| NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS | Press release | PR Newswire | +1.13% | -4.45% | |
| NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" | Press release | PR Newswire | +4.76% | -0.12% | |
| Form 6-K NeuroSense Therapeutics For: Jun 29 | SEC filing · Form 6-K | SEC EDGAR | -9.05% | -18.45% | |
| NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS | Press release | PR Newswire | -3.53% | -18.40% | |
| Form 6-K NeuroSense Therapeutics For: Jun 25 | SEC filing · Form 6-K | SEC EDGAR | -6.24% | -5.24% | |
| NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease | Press release | PR Newswire | -6.24% | -5.24% | |
| EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots | Press release | PR Newswire | +0.85% | -4.71% | |
| Form 6-K NeuroSense Therapeutics For: Jun 11 | SEC filing · Form 6-K | SEC EDGAR | -1.65% | -0.14% | |
| NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS | Press release | PR Newswire | -1.65% | -0.14% | |
| Form 6-K NeuroSense Therapeutics For: Jun 09 | SEC filing · Form 6-K | SEC EDGAR | — | -4.34% | |
| NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition | Press release | PR Newswire | -3.81% | -6.99% | |
| Form 6-K NeuroSense Therapeutics For: Jun 08 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -2.40% | |
| Form 6-K NeuroSense Therapeutics For: Apr 28 | SEC filing · Form 6-K | SEC EDGAR | +0.25% | -0.05% | |
| NeuroSense Announces Pricing of Insider-Led PIPE Financing | Press release | PR Newswire | +9.20% | +3.92% | |
| Form 6-K NeuroSense Therapeutics For: Apr 24 | SEC filing · Form 6-K | SEC EDGAR | -1.22% | +2.89% | |
| Form 6-K NeuroSense Therapeutics For: Apr 06 | SEC filing · Form 6-K | SEC EDGAR | +2.38% | -9.29% | |
| NeuroSense Granted Brazilian Patent Covering PrimeC Composition | Press release | PR Newswire | +2.38% | -9.29% | |
| Form 6-K NeuroSense Therapeutics For: Apr 03 | SEC filing · Form 6-K | SEC EDGAR | +2.38% | -9.29% | |
| NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements | Press release | PR Newswire | +2.38% | -9.29% | |
| Form 20-F NeuroSense Therapeutics For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -2.74% | +3.42% | |
| Form 6-K NeuroSense Therapeutics For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | -2.74% | +3.42% | |
| NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update | Press release | PR Newswire | -2.74% | +3.42% | |
| Form 6-K NeuroSense Therapeutics For: Mar 24 | SEC filing · Form 6-K | SEC EDGAR | -3.22% | -2.10% | |
| NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout | Press release | PR Newswire | -0.77% | -3.41% | |
| PrimeC New Data to Be Presented at AD/PD™ 2026 Conference | Press release | PR Newswire | +1.62% | -4.38% | |
| Form 6-K NeuroSense Therapeutics For: Mar 16 | SEC filing · Form 6-K | SEC EDGAR | -4.35% | -0.22% | |
| JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity | Press release | PR Newswire | +9.94% | -6.76% | |
| Form 6-K NeuroSense Therapeutics For: Mar 11 | SEC filing · Form 6-K | SEC EDGAR | -0.35% | +2.69% | |
| PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference | Press release | PR Newswire | +0.01% | -2.85% | |
| Form 6-K NeuroSense Therapeutics For: Feb 18 | SEC filing · Form 6-K | SEC EDGAR | -6.71% | -18.75% | |
| NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS | Press release | PR Newswire | -6.71% | -18.75% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NRSN section they belong to.
Where else NRSN is measured.
NRSN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is NeuroSense Therapeutics Ltd. - Ordinary Shares's median reaction calculated?
Every labeled NRSN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 260 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of NRSN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NRSN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.